2015年

Bangham C, Taylor G, Yamano Y, Araujo A.
HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).
Nature Reviews Disease Primers, 1, 2015.

Yamauchi J, Coler-Reilly A, Sato T, Araya N, Yagishita N, Ando H,  Kunitomo Y, Takahashi K, Tanaka Y, Shibagaki Y, Nishioka K, Nakajima T, Hasegawa Y, Utsunomiya A, Kimura K, Yamano Y.
Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy.
J Infect Dis, 211(2):238-248, 2015.

Martin F, Inoue E, Cortese ICM, de Almeida Kruschewsky R, Adonis A, Grassi MFR, Galvao-Castro B, Jacobson S, Yamano Y, Taylor GP, Bland M.
Timed walk as primary outcome measure of treatment response in clinical trials for HTLV-1-associated myelopathy: a feasibility study.
Pilot and Feasibility Studies 2015, 1:35, 2015.

Yamano Y.
How does human T-lymphotropic virus type 1 cause central nervous system disease? The importance of cross-talk between infected T cells and astrocytes.
Clin Exp Neuroimmunol, 6(4):395-401, 2015.

Kuramitsu M, Okuma K, Yamochi T, Sato T, Sasaki D, Hasegawa H, Umeki K, Kubota R, Sobata R, Matsumoto C, Kaneko N, Naruse I, Yamagishi M, Nakashima M, Momose H, Araki K, Mizukami T, Mizusawa S, Okada Y, Ochiai M, Utsunomiya A, Koh KR, Ogata M, Nosaka K, Uchimaru K, Iwanaga M, Sagara Y, Yamano Y, Satake M, Okayama A, Mochizuki M, Izumo S, Saito S, Itabashi K, Kamihira S, Yamaguchi K, Watanabe T, Hamaguchi I.
Standardization of Quantitative PCR for Human T-cell Leukemia Virus Type 1 in Japan: A Collaborative Study.
J Clin Microbiol, 53(11):3485-3491, 2015.

Usuba A, Yamashiro T, Handa H, Matsuoka S, Yamano Y, Miyazawa T, Mineshita M.
Quantitative Computed Tomography Measurement of Tracheal Cross-Sectional Areas in Relapsing Polychondritis: Correlations with Spirometric Values.
Respiration, 90(6):468-473, 2015.

Ishihara M, Araya N, Sato T, Saichi N, Fujii R, Yamano Y, Sugano S, Ueda K.
A plasma diagnostic model of human T-cell leukemia virus-1 associated myelopathy.
Ann Clin Transl Neurol, 2(3):231-240, 2015.

Fujita H, Yagishita N, Aratani S, Saito-Fujita T, Morota S, Yamano Y, Hansson MJ, Inazu M, Kokuba H, Sudo K, Sato E, Kawahara KI, Nakajima F, Hasegawa D, Higuchi I, Sato T, Araya N, Usui C, Nishioka K, Nakatani Y, Maruyama I, Usui M, Hara N, Uchino H, Elmer E, Nishioka K, Nakajima T.
The E3 ligase synoviolin controls body weight and mitochondrial biogenesis through negative regulation of PGC-1β.
EMBO J, 34(8):1042-1055, 2015.

Shimizu J, Oka H, Yamano Y, Yudoh K, Suzuki N.
Cardiac involvement in relapsing polychondritis in Japan.
Rheumatology, 55(3):583-584, 2016.

Usuba A, Handa H, Inoue T, Azagami S, Yamano Y, Mineshita M, Miyazawa T, Baumbach JI.
Breath analysis for relapsing polychondritis assessed by ion mobility spectrometry.
Int J Ion Mobil Spec, 18(3):177-183, 2015.

石塚賢治、山野嘉久、宇都宮與、内丸薫.
HTLV-1キャリア外来の実態調査.
臨床血液, 56(6):666-672, 2015.

山野嘉久.
HTLV-1関連脊髄症（HAM）－分子病態解明による治療薬開発の新展開.
医学のあゆみ, 255(5):485-490, 2015.

山野嘉久、新谷奈津美、八木下尚子、佐藤知雄.
免疫性神経疾患－基礎・臨床研究の最新知見－.
日本臨牀, 73(7)：546-553, 2015.

山野嘉久.
日本初、希少難病HAMに対する革新的治療薬の開発.
ビオフィリア電子版, 4(2):43-49, 2015.

山野嘉久.
HTLV-1関連脊髄症（HAM）.
難病事典, 編集責任：尾崎承一, 2-5/511, 2015.